SAN DIEGO, Nov. 29, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced that ten presentations featuring Decipher®Prostate and Bladder data will be presented at the 17th Annual Meeting of the Society of Urologic Oncology (SUO), being held November 30 to December 2, 2016, at the Grand Hyatt San Antonio. Data presentations include four
"Collaboration with academic researchers is a key part of our strategy to use genomic information to improve management of patients with urologic cancers. The nine studies being presented from our Decipher Prostate Cancer Classifier tests showcase the depth of validation research we continue to conduct – with more than 4,000 samples already committed to studies for Decipher Biopsy alone," said Doug Dolginow, M.D., chief executive officer of GenomeDx. "In addition, we continue to see promising data come from our studies of the Decipher Bladder test, and will further evaluate this test's clinical potential."
Decipher Biopsy Podium Presentation: Title: Evaluation of the Decipher Prostate Cancer Classifier to Predict Metastasis and Disease-Specific Mortality from Genomic Analysis of Diagnostic Prostate Needle Biopsy SpecimensPresentation Number: Oral abstract session, presentation #6Date: Friday, Dec. 2 (2:00 p.m. to 2:45 p.m. CST)Presenter: Voleak Choeurng, MSc., GenomeDx Biosciences
Decipher Biopsy Poster Presentations: Title: Decipher Correlation Patterns on Biopsy: Initial Experience from 738 Prospective PatientsPresentation Number: 99Date: Wednesday, Nov. 30 (4:30 p.m. to 6:00 p.m. CST)Presenter: Ashley Ross, M.D., Ph.D., Johns Hopkins School of Medicine
Title: The Heterogeneous Genomic Landscape of Low-Risk Prostate Cancer Presentation Number: 115Date: Wednesday, Nov. 30 (4:30 p.m. to 6:00 p.m. CST)Presenter: Matthew Cooperberg, M.D., MPH, University of California, San Francisco
Title: Transcriptome Wide Analysis of MRI-Targeted Biopsy and Matching Surgical Specimens from High-Risk Prostate Cancer Patients Treated with Radical Prostatectomy Presentation Number: 126Date: Wednesday, Nov. 30 (4:30 p.m. to 6:00 p.m. CST)Presenter: Peter Black, M.D., University of British Columbia
Decipher Post-Op Poster Presentations: Title: Decipher Test Impacts Adjuvant Treatment Decision-Making Among Patients with High-Risk Pathology at Radical Prostatectomy: Results from the Multicenter Prospective PRO-IMPACT Study Presentation Number: 75 Date: Wednesday, Nov. 30 (4:30 p.m. to 6:00 p.m. CST)Presenter: Daniel Lin, M.D., University of Washington
Title: Decipher Test Impacts Treatment Decision-Making Among Patients with Biochemical Recurrence After Radical Prostatectomy: Results from the Multicenter Prospective PRO-IMPACT Study Presentation Number: 76Date: Wednesday, Nov. 30 (4:30 p.m. to 6:00 p.m. CST)Presenter: Daniel Lin, M.D., University of Washington
Title: Assessing Decipher for Predicting Lymph Node Positive Disease Among Men Diagnosed with Intermediate Risk Disease Treated with Prostatectomy and EPLNDPresentation Number: 93Date: Wednesday, Nov. 30 (4:30 p.m. to 6:00 p.m. CST)Presenter: John Davis, M.D., The University of Texas MD Anderson Cancer Center
Title: Individual Patient Level Meta-Analysis of the Performance of the Decipher Genomic Classifier in High Risk Men Post-Prostatectomy to Predict Development of Metastatic Disease Presentation Number: 94Date: Wednesday, Nov. 30 (4:30 p.m. to 6:00 p.m. CST)Presenter: Elai Davicioni, Ph.D., GenomeDx Biosciences
Title: Comparative Analysis of the Decipher Genomic Classifier and CAPRA-S Nomogram Between African American and Caucasian PopulationsPresentation Number: 237Date: Thursday, Dec. 1 (4:55 p.m. to 6:25 p.m. CST)Presenter: Walter Rayford, M.D., Ph.D., University of Tennessee
Decipher Bladder Poster Presentation: Title: Muscle Invasive Bladder Cancer: Molecular Subtypes are Related to Benefit of Neoadjuvant ChemotherapyPresentation Number: 143Date: Thursday, Dec. 1 (4:55 p.m. to 6:25 p.m. CST)Presenter: Peter Black, M.D., University of British Columbia
About Decipher GRID® and Decipher® Prostate Cancer Classifier Tests
GenomeDx's Decipher Genomics Resource Information Database (GRID) contains genomic profiles of thousands of tumors from patients with urological cancers, and is believed by GenomeDx to be the largest shared genomic expression database in urologic cancer as well as one of the world's largest global RNA expression databases using cloud-based analytics. GRID is a platform for interactive research collaboration, and may enable more rapid discovery, development, commercialization and adoption of new genomic solutions for key clinical questions in cancer treatment.
Derived from GRID, GenomeDx's Decipher Prostate Cancer Classifier tests are commercially available genomic tests that provide a genomic assessment of tumor aggressiveness for individual patients. Decipher Biopsy is indicated for men with localized prostate cancer at diagnosis, and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups than determined by traditional diagnostic tools and to better determine which patients may be more likely to benefit from additional treatment. Each tumor analyzed with a Decipher test adds new data points to the GRID database, which is compiled into a Decipher GRID Profile that may reveal additional biological characteristics of the tumor for ongoing research purposes. Going beyond risk stratification, Decipher and GRID makes accessible genetic information for researchers to potentially better predict responses to therapy and more precisely guide treatment.
More information is available at www.deciphertest.com and www.deciphergrid.com.
About GenomeDx Biosciences
GenomeDx has reimagined the use of genomics as a platform for mass collaboration to improve treatment and outcomes of people with cancer. GenomeDx has built Decipher GRID, a large and fast-growing genomics database in urologic cancer that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID and machine learning to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that are intended to provide more accurate and useful diagnostic information than traditional diagnostic tools or existing genomic tests. GenomeDx's Decipher Biopsy and Decipher Post-Op are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is headquartered in Vancouver, British Columbia and operates a clinical laboratory in San Diego, California.
Learn more at www.GenomeDx.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genomedxs-decipher-prostate-and-bladder-data-to-be-featured-in-multiple-presentations-at-17th-annual-meeting-of-the-society-of-urologic-oncology-300369445.html
SOURCE GenomeDx Biosciences
Subscribe to our Free Newsletters!
Hypopituitarism is a rare disorder resulting from decreased secretion of one or more of the ...
Palliative care is a specialized multifaceted care for patients with chronic or terminal illness to ...
Our kitchen and food has the best medicinal properties to fight stress. These are the top 10 foods ...View All